Evidence map›Paper›PMID 40635447›Full record

ArticleDrug delivery2025

Immunomodulator loaded microneedle arrays for targeted intradermal drug delivery to skin tumors.

Akmal H Sabri, Fiona Smith, Zachary Cater, Pratik Gurnani, Ami Nash, Victoria Brentville, Lindy Durrant, John McKenna, Joel Segal, David J Scurr and 1 more

Abstract read
In one paragraph

Article in Drug delivery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Akmal H SabriSchool of Pharmacy, University of Nottingham, Nottingham, UK.
Fiona SmithSchool of Pharmacy, University of Nottingham, Nottingham, UK.
Zachary CaterAdvanced Manufacturing Technology Research Group, Faculty of Engineering, University of Nottingham, Nottingham, UK.
Pratik GurnaniSchool of Pharmacy, University of Nottingham, Nottingham, UK.
Ami NashSchool of Pharmacy, University of Nottingham, Nottingham, UK.
Victoria BrentvilleScancell Ltd, University of Nottingham Biodiscovery Institute, Nottingham, UK.
Lindy DurrantScancell Ltd, University of Nottingham Biodiscovery Institute, Nottingham, UK.
John McKennaLeicester Royal Infirmary University Hospitals Leicester Dermatology Department, Infirmary Square, Leicester, UK.
Joel SegalAdvanced Manufacturing Technology Research Group, Faculty of Engineering, University of Nottingham, Nottingham, UK.
David J ScurrSchool of Pharmacy, University of Nottingham, Nottingham, UK.
Maria MarlowSchool of Pharmacy, University of Nottingham, Nottingham, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Topical therapy with imiquimod in a cream [5% w/w imiquimod cream (Aldara™)] for the treatment of nodular basal cell carcinoma (BCC) currently results in low cure rates, attributed to low imiquimod permeation. Herein we have developed novel microneedle array patches (MAPs), to maximize imiquimod intradermal delivery and retention in the skin, with potential as an efficacious treatment for BCC. Enhanced delivery of imiquimod in pig skin and

Indexed as

AminoquinolinesAntineoplastic AgentsBasal Cell CarcinomaDrug Delivery SystemsSkin NeoplasmsAdministration, CutaneousAnimalsCell Line, TumorHumansImiquimodMiceMicroinjectionsNeedlesSkinSkin AbsorptionSwineAminoquinolinesAntineoplastic AgentsImiquimodbasal cell carcinomaimiquimodmass spectrometryMicroneedlesskin permeationToF-SIMS

Identifiers

PMID40635447
PMCPMC12247101

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.